RNS Just Out (Great News!!!!!!!)27 Apr 2011 08:46
Akers Biosciences, Inc.
("ABI" or the "Company")
ABI Granted Patent Protection for Semi-quantitative Test Strip
Akers Biosciences, Inc (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, is pleased to announce that it has been granted patent protection in the United States for its novel, semi-quantitative test strip technology (the "Technology"), which enables the rapid determination of levels of important markers of disease. The Technology forms a key element of the Company's Tri-Cholesterol test - the only rapid test in the US to determine Total HDL and LDL cholesterol levels. The Technology could also be applied to many other diagnostic tests that can be marketed to both doctors' surgeries and consumers.
ABI's novel Technology facilitates the rapid, semi-quantitative analysis of biomarkers in bodily fluids within a convenient, on-site setting. The intellectual property encompasses certain elements of a system of membranes, as well as a means for the semi-quantitative estimation of the level of the biomarker. The concentration of certain biomarkers such as prostate-specific antigen, an important marker of prostate cancer, or cholesterol in the blood are important diagnostic tools necessary to monitor the risk or progression of disease. However, precise quantitative determinations are not necessary for the clinical utility of these biomarkers, but rather an estimate of the concentration suffices for screening purposes. By contrast, conventional methods are labour-intensive and time-consuming, and may involve specialised equipment and/or medical personnel to determine the concentration of the test substance.
Dr Raymond F. Akers, Jr., Executive Chairman, commented:
"We are pleased that another one of our core platform technologies has obtained patent protection. Our semi-quantitative test strip technology provides doctors and consumers with the ability to determine levels of important markers of disease inexpensively, at the Point-of-Care and without the complications of costly and difficult-to-operate medical instruments. Furthermore, the Technology provides users with fast and easy screening test results when precise measurement is not necessary. For example, what is most important to a patient with concerns about his cholesterol is whether his cholesterol level is higher or lower than it was last month. By putting the power of this type of information right when and where it is needed, immediate action can be taken."